.jetcityimage/iStock Editorial via Getty Images Morgan Stanley has actually picked Eli Lilly (NYSE: LLY) as its own leading biopharma selection for 2025 and also rated an additional 9 labels in the room as over weight. The expenditure financial institution said in a note that it remains to strongly believe “diabesity is set to come to be.